Full text is available at the source.
Abstract
This cross-sectional study examines glucagon-like peptide-1 (GLP-1) prescriptions among adults with and without severe mental illness from 2018 to 2024.
- GLP-1 prescriptions are analyzed using national insurance claims data.
- The study focuses on adults diagnosed with severe mental illness compared to those without such diagnoses.
- Trends in prescription rates may differ between the two groups over the specified timeframe.
- The findings could provide insights into healthcare access and treatment patterns for individuals with severe mental illness.
Simplified